Straits Times Index
3,230.55 +21.37 (+0.67%) Nikkei
26,781.68 +176.84 (+0.66%) Hang Seng
20,697.36 +581.16 (+2.89%) FTSE 100
7,585.46 +20.54 (+0.27%) BTC-USD
28,811.13 -215.66 (-0.74%) CMC Crypto 200
625.79 -3.71 (-0.59%)
Bristol-Myers Squibb Company (BMY)
After hours:
| Previous close | 77.59 |
| Open | 77.31 |
| Bid | 76.25 x 1800 |
| Ask | 76.35 x 800 |
| Day's range | 75.46 - 77.44 |
| 52-week range | 53.22 - 78.61 |
| Volume | |
| Avg. volume | 15,212,149 |
| Market cap | 162.107B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 26.97 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.16 (2.78%) |
| Ex-dividend date | 31 Mar 2022 |
| 1y target est | N/A |
- Business Wire
U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
PRINCETON, N.J., May 27, 2022--US FDA Approves Two Opdivo-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Business Wire
Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
PRINCETON, N.J., May 26, 2022--Data from Phase 2 PILOT Study of BMS’s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients....
- Business Wire
Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference
NEW YORK, May 26, 2022--Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Bernstein’s 38th Annual Strategic Decisions Conference in New York, New York on Thursday, June 2, 2022. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer and Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, will answer questions about the company at 8:00 a.m. ET.
